Fernanda Flygare: HI-PEITHO Trial Highlights Benefits of EKOS-Assisted Catheter-Directed Thrombolysis in PE
Fernanda Flygare, Marketing manager at Boston Scientific, shared on LinkedIn:
”In intermediate-risk pulmonary embolism, anticoagulation alone may not always be sufficient to prevent hemodynamic deterioration.
The HI-PEITHO trial provided important evidence showing that ultrasound-assisted catheter-directed thrombolysis with the EKOS system, combined with anticoagulation, reduced clinically relevant outcomes while contributing to greater patient stability without increasing major bleeding.
In this video, Dr. Felipe Nasser, specialist in Interventional Radiology and Endovascular Surgery, shares his perspective on how these findings may translate into clinical practice and impact patient management.
At Boston Scientific, we remain committed to advancing continuous medical education and fostering high-level clinical discussions that support evidence-based decision-making and ultimately improve patient care.
Congratulations to everyone involved in bringing valuable scientific exchange and education to the medical community.
Stay updated with Hemostasis Today.
-
Aug 28, 2026, 16:44HEMGENIX Supply Update for the Hemophilia B Community – National Bleeding Disorders Foundation
-
Aug 28, 2026, 16:39Maria Elisa Mancuso: Attending EHC 2026 Annual Conference in Istanbul
-
Aug 28, 2026, 16:25Manali Kakadia: Evaluation and Management of Recurrent Epistaxis
-
Aug 28, 2026, 16:18Navigating Higher Education with a Bleeding Disorder – Bleeding Disorders Council of California
-
Aug 28, 2026, 16:11Maia Meier: Reaching New Heights for Women With Inherited Bleeding Disorders
-
Aug 28, 2026, 15:10Ify Osunkwo: Strengthening Sickle Cell Care Systems at Global Conference in Nairobi
-
Aug 28, 2026, 15:08Muhammed Safvan: One Drop of Blood Can Tell a Story
-
Aug 28, 2026, 14:52Jessica Lee: Standing Together for Children and Families with Bleeding Disorders
-
Aug 28, 2026, 14:45Daisy Souster: A New Chapter in Bleeding Disorder Advocacy